Pfizer’s Sutent fails in breast cancer trials

Pfizer has suffered a couple of late-stage clinical setbacks with the news that its oncology blockbuster Sutent has failed in two trials for breast cancer while another study of figitumumab.for lung cancer has been stopped

Ipsen signs obesity deal with Rhythm

Ipsen has granted a licence to the USA’s Rhythm Pharmaceuticals to take over two of its metabolic disorders